肿瘤热疗的研究进展

肿瘤热疗是近年来研究的热点.肿瘤热疗后宿主机体的免疫功能发生变化,宿主全身抗肿瘤免疫反应被激活.本文从基础研究和临床试验两个方面对热疗后机体免疫功能的改变及其杀伤肿瘤的机理作一综述.     

NLRP6在抗细菌感染免疫中的作用研究进展

含热蛋白结构域的核苷酸结合寡聚化结构域样受体蛋白6(nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 6,NLRP6)是宿主固有免疫重要的胞内模式识别受体之一,参与机体感染、炎症、肿瘤和代谢性疾病的调节。它可通过感知细菌、病毒、真菌和寄生虫等病原生物及其产物,如革兰氏阳性菌脂磷壁酸(lipoteichoic acid, LTA)和病毒双链RNA,调节机体抗感染免疫效应,减弱或增强宿主的抵抗力,从而影响感染的转归。本文就NLRP6的结构与功能及其在抗细菌感染免疫中的作用研究作综述。     

小鼠腹腔巨噬细胞被S-O_2-I菌苗激活后的抑瘤作用——Ⅱ.小鼠腹腔巨噬细胞被动转移的抑瘤效应及其肿瘤的病理观察

众所周知肿瘤的发展受宿主免疫功能的影响,当机体免疫功能下降时,肿瘤发展快,死亡率也高。卡介苗和厌氧棒状杆菌苗等一类的细菌佐剂能提高机体的免疫功能,增强机体对肿瘤细胞的排斥能力,它们的抗肿瘤活性和临床应用已有大量报道(Cross et al.,1976;Yamamura et al.,1979;Woodruff et al.,1975;Isral et al.,1976)。近年来,发现S-O_2-1菌苗在临床试用中,具有一定的抗肿瘤活性,并且副作用小,因     

microRNAs在肿瘤免疫中的调控作用

microRNAs（miRNAs）是一类转录后调控基因表达的内源性非编码微小RNA。愈来愈多的研究显示,miRNAs在肿瘤免疫应答中发挥重要调控作用。一方面,miRNAs通过转录后调控ICAM（intercellular adhesion molecule）、B7（CD80／86）和HLA—G（human leucocyte antigen—G）等肿瘤表面分子的表达,影响肿瘤的免疫原性;另一方面,miRNAs通过平衡肿瘤局部的细胞因子微环境或调控肿瘤免疫相关细胞的分化、发育及功能发挥,调节机体抗肿瘤免疫应答。为后续深入研究肿瘤与宿主的相互作用机制,以及发展更有效的肿瘤生物治疗手段,就目前miRNAs在肿瘤免疫中的调控作用的研究进展做一综述。     

病毒感染对宿主肠道微生态的影响

肠道菌群对宿主免疫系统的建立和发育起着重要的作用,与宿主的生理、病理等密切相关,对机体抗病毒作用具有一定的影响。病毒感染影响宿主肠道微生物群落,进而影响宿主机体营养物质的代谢及细胞免疫功能。本研究着重综述病毒感染对宿主肠道微生态及免疫的影响。     

病毒感染对宿主肠道微生态的影响

摘要：肠道菌群对宿主免疫系统的建立和发育起着重要的作用,与宿主的生理、病理等密切相关,对机体抗病毒作用具有一定的影响。病毒感染影响宿主肠道微生物群落,进而影响宿主机体营养物质的代谢及细胞免疫功能。本研究着重综述病毒感染对宿主肠道微生态及免疫的影响。     

人巨细胞病毒博弈宿主免疫进展

人巨细胞病毒(HCMV)感染在人群中极其普遍,病毒一旦侵入机体,将长期存在于体内,且具有潜伏-活化的生物学特性。在病毒与宿主共同进化的漫长过程中,病毒靶向性的产生了多种免疫逃避机制,通过编码病毒自身免疫调节分子,参与调控机体主要组织相容性复合体、细胞免疫、体液免疫、细胞因子及趋化因子等方面的功能,以躲避宿主的免疫杀伤作用。HCMV的免疫调节基因被认为在病毒的致病机制中扮演重要角色。本文将对近年来有关HCMV的免疫调控机制研究作一综述,从病毒编码的免疫调节分子功能的角度并结合本实验室的相关研究成果,探讨病毒与宿主免疫的相互作用过程,从病毒干预宿主免疫关键分子作用的角度映射机体对抗病毒的免疫机理。     

麻醉对免疫抑制与肿瘤复发的影响

术后肿瘤复发是导致患者死亡的主要原因。大量研究表明:围手术期患者的免疫功能与肿瘤复发密切相关,而麻醉药物或方法对机体免疫功能的抑制是导致肿瘤复发的重要因素。因此,本文拟就麻醉药物或方法对围手术期免疫功能和肿瘤复发的影响进行综述。     

肿瘤免疫逃逸机制的研究进展

肿瘤是目前全球人类主要死亡原因之一,它给人类生命健康造成了巨大威胁。现已发现其发生、发展、转移与机体的免疫系统密切相关。免疫系统可通过多种途径杀伤和清除肿瘤,对其有一定的控制作用,然而肿瘤往往仍能在机体内生长,这表明肿瘤细胞能够逃避或反击宿主免疫系统,使机体不能产生有效的抗肿瘤免疫应答。阐明肿瘤免疫逃逸机制是预防、诊断、治疗肿瘤的关键,文章将对肿瘤免疫逃逸机制的研究进展做一综述。     

丙型肝炎病毒基因突变与免疫逃逸

免疫逃逸（Immune evasion）是指病原体逃避机体免疫监控的现象。在宿主和病毒的长期共同进化过程中,病毒形成了各种逃选机制以逃避宿主的免疫监控,其中病毒基因变异是最主要机制。丙型肝炎病毒（Hepatitis C virus,HCV）在感染个体中表现出极高的基因异质性,能有效地逃逸机体免疫识剐和破坏宿主免疫应答的能力,HCV还可侵袭免疫细胞来抑制机体的免疫功能,而建立HCV持续性感染。了解HCV病毒突变与免疫逃逸机制将会为预防和控制丙型肝炎提供依据。     

Intra-Peritoneal Hyperthermia Combining α-Galactosylceramide in the Treatment of Ovarian Cancer

The purpose of this study was to investigate the anti-tumor effect and potential mechanisms of i.p. hyperthermia in combination with α-galactosylceramide (α-GalCer) for the treatment of ovarian cancer. In this study, immuno-competent tumor models were established using murine ovarian cancer cell lines and treated with i.p. hyperthermia combining α-GalCer. Th1/Th2 cytokine expression profiles in the serum, NK cell cytotoxicity and phagocytic activities of dendritic cells (DCs) were assayed. We also analyzed the number of CD8⁺/IFN-γ⁺ tumor specific cytotoxic T cells, as well as the tumor growth based on depletion of lymphocyte sub-population. Therapeutic effect on those ovarian tumors was monitored by a non-invasive luminescent imaging system. Intra-peritoneal hyperthermia induced significant pro-inflammatory cytokines expression, and sustained the response of NK and DCs induced by α-GalCer treatment. The combination treatment enhanced the cytotoxic T lymphocyte (CTL) immune response in two mouse ovarian cancer models. This novel treatment modality by combination of hyperthermia and glycolipid provides a pronounced anti-tumor immune response and better survival. In conclusion, intra-peritoneal hyperthermia enhanced the pro-inflammatory cytokine secretion and phagocytic activity of DCs stimulated by α-GalCer. The subsequent CTL immune response induced by α-GalCer was further strengthened by combining with i.p. hyperthermia. Both innate and adaptive immunities were involved and resulted in a superior therapeutic effect in treating the ovarian cancer.     

Activation of local and systemic anti-tumor immune responses by ablation of solid tumors with intratumoral electrochemical or alpha radiation treatments

Cancer, the most devastating chronic disease affecting humankind, is treated primarily by surgery, chemotherapy, and radiation therapy. Surgery and radiotherapy are mainly used for debulking the primary tumor, while chemotherapy is the most efficient anti-metastatic treatment. To control better metastatic cancer, the host immune system should be stimulated. Yet, successful specific stimulation of the immune system against tumors was seldom achieved even in antigenic tumors. Our working hypothesis is that aggressive in situ tumor ablation can release tumor antigens and danger signals, which will enhance anti-tumor T cell responses resulting in the destruction of residual malignant cells in primary tumors and distant metastases. We developed two efficient in situ ablation treatments for solid cancer, which can be used to destroy the primary tumors and stimulate anti-tumor immune responses. The first treatment, electrochemical ablation, is applied through intratumoral electrodes, which deliver unipolar-pulsed electric currents. The second treatment, diffusing alpha-emitters radiation therapy (DaRT), is based on intratumoral ²²⁴Ra-loaded wire(s) that release by recoil its daughter atoms. These short-lived alpha-emitting atoms spread in the tumor and spray it with lethal alpha particles. It was confirmed that these treatments effectively destroy various malignant animal and human primary solid tumors. As a consequence of such tumor ablation, tumor-derived antigenic material was released and provoked systemic T cell-dependent anti-tumor immunological reactions. These reactions conferred protection against a secondary tumor challenge and destroyed remaining malignant cells in the primary tumor as well as in distant metastases. Such anti-tumor immune responses could be further amplified by the immune adjuvant, CpG. Electrochemical ablation or DaRT together with chemotherapy and immunostimulatory agents can serve as treatment protocols for solid metastatic tumors and can be applied instead of or in combination with surgery.     

番茄红素联合CIK 治疗的抗肿瘤作用的实验研究

目的:探讨番茄红素联合细胞因子诱导的杀伤细胞(CIK)治疗的抗肿瘤作用及相应机制。方法:建立荷B16-F10黑色素瘤小鼠模型,观察联合治疗对肿瘤体积、宿主生存时间、淋巴细胞增殖活力及淋巴细胞杀伤能力的影响。结果:CIK及番茄红素治疗均可以抑制肿瘤的生长,延长荷瘤鼠的生存时间。与CIK治疗组相比较,中高剂量的番茄红素联合CIK治疗可以显著增强抗肿瘤疗效,延长荷瘤鼠的生存时间,并且可以通过刺激荷瘤鼠淋巴细胞增殖、增强淋巴细胞对肿瘤的杀伤能力提高CIK治疗的抗肿瘤疗效。结论:番茄红素能够通过提高宿主免疫水平而显著增强CIK治疗的抗肿瘤效果。     

Ganoderma atrum polysaccharide induces anti-tumor activity via the mitochondrial apoptotic pathway related to activation of host immune response

Ganoderma atrum polysaccharide (PSG-1), the major active ingredient isolated from Ganoderma atrum, has been suggested as a candidate for cancer therapy. The aim of this study was to investigate the anti-tumor effect of PSG-1 using sarcoma 180 (S-180) transplanted mice and further to examine the molecular mechanisms of PSG-1-induced anti-tumor effect. Results showed that PSG-1 significantly inhibited tumor growth in S-180-bearing mice. PSG-1-induced tumor apoptosis was associated with the alteration of Bcl-2 family proteins, increase of reactive oxygen species generation, loss of mitochondrial membrane potential (Δψ(m) ), release of cytochrome c from the mitochondria into cytosol, and activation of caspase-3 and -9. Elevation of immune function was also shown during PSG-1-induced tumor apoptosis, as evidenced by increase of spleen and thymus indexes, lymphocyte proliferation, concentrations of tumor necrosis factor (TNF)-α, and interleukin-2 in serum. Furthermore, the combined treatment of PSG-1 and cyclophosphamide (CTX) results in an enhancement of the anti-tumor effect of CTX alone via increased host immune response. These results suggested that PSG-1 had a potent anti-tumor activity by induction of tumor apoptosis through mitochondrial pathways, and immunoenhancement effect of PSG-1 was related to its anti-tumor effect. In addition, PSG-1 enhanced CTX-induced anti-tumor activity in S-180-bearing mice.     

综述: 代谢重编程在调控肿瘤免疫微环境中的作用

肿瘤免疫治疗的成功揭示了宿主免疫在抵抗癌细胞增殖方面的重要作用以及抗肿瘤免疫治疗的可行性．但是具有免疫抑制作用的肿瘤微环境仍然是限制肿瘤免疫治疗进展的重要瓶颈．肿瘤微环境会诱发肿瘤细胞代谢发生重编程,此过程会导致肿瘤细胞与宿主免疫细胞竞争利用营养物质,肿瘤细胞来源的代谢产物或废物可通过多种方式影响免疫细胞的激活及效应功能的发挥,最终达到促使肿瘤细胞存活及增殖的目的．因此,本文就微环境条件下肿瘤细胞代谢重编程及其代谢产物对免疫微环境的影响展开讨论,以期为肿瘤免疫治疗提供理论基础及新的思路．     

肿瘤相关巨噬细胞极化的研究进展

肿瘤相关巨噬细胞是肿瘤组织局部浸润的巨噬细胞,在肿瘤组织微环境中,这些巨噬细胞发生M2型极化,从而发挥免疫抑制效应,促进肿瘤增殖。而M2型极化的肿瘤相关巨噬细胞也能够被再次诱导逆向极化形成具有抗肿瘤效应的M1型肿瘤相关巨噬细胞,激发机体产生特异性抗肿瘤免疫应答。促进肿瘤相关巨噬细胞M1型极化由此成为当前抗肿瘤免疫防治研究的热点。将对有关肿瘤相关巨噬细胞极化的新进展进行综述,为抗肿瘤免疫研究提供新的思路。     

Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity

Promising anti-tumor responses have been observed in the clinic using monoclonal antibodies (mAbs) that block immune checkpoints. One concern with these therapeutic agents remains the potential induction of immune breakthrough events (IBEs) resulting from the disruption of T cell homeostasis or the breaking of tolerance to self antigens. As an approach to maintaining anti-tumor responses but decreasing the likelihood of these events, the local expression of a mAb in combination with a GM-CSF-secreting cancer immunotherapy was evaluated. Using anti-cytotoxic T lymphocyte antigen (CTLA)-4 as a model antibody to test this hypothesis, tumor cell lines were generated that expressed the full-length mAb in addition to GM-CSF. Evaluation of these cell lines in two therapeutic tumor models revealed that local, cell-mediated delivery of anti-CTLA-4 from a GM-CSF-secreting tumor cell immunotherapy activated potent anti-tumor responses and prolonged overall survival at significantly lower serum mAb levels in the host. Furthermore, lowering the systemic exposure of the host to the immune modulatory mAb correlated with reduced evidence of systemic autoimmunity. This approach has broad utility for the delivery of mAbs or proteins locally from cellular immunotherapies to minimize IBEs while retaining the potent therapeutic effects of such combination treatments.     

Ideas in Theoretical Biology - Failure of Anti-Tumor Immunity in Mammals - Evolution of the Hypothesis

Observations on the morphological and functional similarity between embryonic or trophoblast tissues and tumors are very old. Over a period of time many investigators have created different hypotheses on the origin of cancerogenesis or tumor efficiency in relation to the host immune system. Some of these ideas have been rejected but many of them are still current. A presumption of the inefficiency of anti-tumor immunity in mammals due to the high similarity between trophoblast and embryonic cells to tumor cells is very real. The mechanisms for the escape of tumors from the immune response are very similar to the mechanisms for the escape of a fetoplacental unit from the maternal immune response. The similarity between these two mechanisms is so great that any randomness must be banished. At the same time, an incidence of malignant tumors and the types of more frequent tumors in non-mammalian vertebrates is significantly different to that in mammals. Lastly, the mechanisms of anti-tumor immunity in mammals are substantially different from the mechanisms of anti-tumor immunity in other classes of vertebrates. These facts indicate that the immune system of mammals during anti-tumor immune response is tricked by the similarity between tumor cells and trophoblast or other placental cells. From this aspect, our conclusion is that anti-tumor immunity failure in mammals can be defined as an immunoreproductive phenomenon, which is developed under the evolutionary pressure of autoimmunity and reproductive effectiveness.     

Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer

Metabolic disorders and abnormal immune function changes occur in tumor tissues and cells to varying degrees. There is increasing evidence that reprogrammed energy metabolism contributes to the development of tumor suppressive immune microenvironment and influences the course of gastric cancer (GC). Current studies have found that tumor microenvironment (TME) also has important clinicopathological significance in predicting prognosis and therapeutic efficacy. Novel approaches targeting TME therapy, such as immune checkpoint blockade (ICB), metabolic inhibitors and key enzymes of immune metabolism, have been involved in the treatment of GC. However, the interaction between GC cells metabolism and immune metabolism and how to make better use of these immunotherapy methods in the complex TME in GC are still being explored. Here, we discuss how metabolic reprogramming of GC cells and immune cells involved in GC immune responses modulate anti-tumor immune responses, as well as the effects of gastrointestinal flora in TME and GC. It is also proposed how to enhance anti-tumor immune response by understanding the targeted metabolism of these metabolic reprogramming to provide direction for the treatment and prognosis of GC.Subject terms: Cancer, Mechanisms of disease